News

Meet Tasman's Chief Scientific Officer at CPHI Milan

September 14, 2026 at 12:30:00 PM

Tasman’s Chief Scientific Officer, Peter Surman, will be at CPHI Milan from 6 - 8 October 2026.

Dr Surman be available to talk about Phase 3 of R-107, the oral extended-release ketamine tablet transforming Treatment Resistant Depression and other depressive disorders, as well as other drug repurposing assets and 505.B2 NDAs.

Send a message through the website contact us form to arrange an appointment at stand 5A17 with Douglas Pharmaceuticals.